Head to Head Review: OncoSec Medical (ONCS) & The Competition
OncoSec Medical (NASDAQ: ONCS) is one of 199 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its peers? We will compare OncoSec Medical to related businesses based on the strength of its institutional ownership, valuation, profitability, earnings, analyst recommendations, dividends and risk.
Earnings & Valuation
This table compares OncoSec Medical and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|OncoSec Medical||N/A||-$21.73 million||-1.08|
|OncoSec Medical Competitors||$206.18 million||-$2.14 million||2.50|
OncoSec Medical’s peers have higher revenue and earnings than OncoSec Medical. OncoSec Medical is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares OncoSec Medical and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|OncoSec Medical Competitors||-3,961.77%||-118.02%||-43.71%|
Risk and Volatility
OncoSec Medical has a beta of 2.94, suggesting that its share price is 194% more volatile than the S&P 500. Comparatively, OncoSec Medical’s peers have a beta of 1.62, suggesting that their average share price is 62% more volatile than the S&P 500.
Institutional and Insider Ownership
9.0% of OncoSec Medical shares are held by institutional investors. Comparatively, 46.9% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 11.5% of OncoSec Medical shares are held by company insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This is a summary of recent ratings and price targets for OncoSec Medical and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|OncoSec Medical Competitors||483||2286||6246||120||2.66|
OncoSec Medical currently has a consensus price target of $5.33, suggesting a potential upside of 365.79%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.68%. Given OncoSec Medical’s stronger consensus rating and higher possible upside, research analysts plainly believe OncoSec Medical is more favorable than its peers.
OncoSec Medical peers beat OncoSec Medical on 7 of the 12 factors compared.
OncoSec Medical Company Profile
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses.
Receive News & Ratings for OncoSec Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.